![Sustainability | Free Full-Text | Climate Smart Regenerative Agriculture to Produce Sustainable Beauty Products: The Case Study of Snail Secretion Filtrate (LX360®) Sustainability | Free Full-Text | Climate Smart Regenerative Agriculture to Produce Sustainable Beauty Products: The Case Study of Snail Secretion Filtrate (LX360®)](https://www.mdpi.com/sustainability/sustainability-14-02367/article_deploy/html/images/sustainability-14-02367-g001.png)
Sustainability | Free Full-Text | Climate Smart Regenerative Agriculture to Produce Sustainable Beauty Products: The Case Study of Snail Secretion Filtrate (LX360®)
![Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2020-0283/asset/images/medium/figure1.gif)
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology
![Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - ScienceDirect Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204522X00090-cov150h.gif)
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - ScienceDirect
![Minerals | Free Full-Text | Relative Abundance and Compositional Variation of Silicates, Oxides and Phosphates in the W-Sn-Rich Lodes of the Panasqueira Mine (Portugal): Implications for the Ore-Forming Process Minerals | Free Full-Text | Relative Abundance and Compositional Variation of Silicates, Oxides and Phosphates in the W-Sn-Rich Lodes of the Panasqueira Mine (Portugal): Implications for the Ore-Forming Process](https://pub.mdpi-res.com/minerals/minerals-10-00551/article_deploy/html/images/minerals-10-00551-ag.png?1594040368)
Minerals | Free Full-Text | Relative Abundance and Compositional Variation of Silicates, Oxides and Phosphates in the W-Sn-Rich Lodes of the Panasqueira Mine (Portugal): Implications for the Ore-Forming Process
![Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - ScienceDirect Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204522003266-gr1.gif)
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - ScienceDirect
![Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape - ScienceDirect Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0929664622001395-gr1.jpg)
Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape - ScienceDirect
![Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/4764937c-9bdd-46ae-b3fb-5d784ce51417/gr2.jpg)
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
![Terahertz Time-Domain Spectroscopy in Reflection Configuration for Inorganic and Mineral Pigment Identification - Alessia Artesani, Raffaella Lamuraglia, Federica Menegazzo, Stefano Bonetti, Arianna Traviglia, 2023 Terahertz Time-Domain Spectroscopy in Reflection Configuration for Inorganic and Mineral Pigment Identification - Alessia Artesani, Raffaella Lamuraglia, Federica Menegazzo, Stefano Bonetti, Arianna Traviglia, 2023](https://journals.sagepub.com/cms/10.1177/00037028221133404/asset/images/large/10.1177_00037028221133404-img1.jpeg)
Terahertz Time-Domain Spectroscopy in Reflection Configuration for Inorganic and Mineral Pigment Identification - Alessia Artesani, Raffaella Lamuraglia, Federica Menegazzo, Stefano Bonetti, Arianna Traviglia, 2023
![Minerals | Free Full-Text | Contamination Fingerprints in an Inactive W (Sn) Mine: The Regoufe Mine Study Case (Northern Portugal) Minerals | Free Full-Text | Contamination Fingerprints in an Inactive W (Sn) Mine: The Regoufe Mine Study Case (Northern Portugal)](https://www.mdpi.com/minerals/minerals-13-00497/article_deploy/html/images/minerals-13-00497-g001.png)
Minerals | Free Full-Text | Contamination Fingerprints in an Inactive W (Sn) Mine: The Regoufe Mine Study Case (Northern Portugal)
![Magnetic crises, political convulsions: The Mesmerists in the Constituent Assembly [1] | Cairn International Edition Magnetic crises, political convulsions: The Mesmerists in the Constituent Assembly [1] | Cairn International Edition](https://www.cairn-int.info/vign_rev/E_AHRF/E_AHRF_391.jpg)
Magnetic crises, political convulsions: The Mesmerists in the Constituent Assembly [1] | Cairn International Edition
![Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma | Nature Communications Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-023-37084-w/MediaObjects/41467_2023_37084_Fig1_HTML.png)
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma | Nature Communications
![COSMIC-312 Cabozantinib Plus Atezolizumab Improves Progression-Free Survival in Advanced Hepatocellular Carcinoma - The ASCO Post COSMIC-312 Cabozantinib Plus Atezolizumab Improves Progression-Free Survival in Advanced Hepatocellular Carcinoma - The ASCO Post](https://ascopost.com/media/14018827/18-kelley.jpg)